More recently, a mate-analysis of five trials on targeting VEGFR-2 in a total of 1,596 patients with advanced gastric cancer demonstrated that anti-VEGFR-2 inhibitors revealed a significant increase in OS [HR: 0.69, 95% CI (0.55, 0.87) p = 0.002] [44]. This evidence concerns the gene KDR and gastric cancer.